科研动态期刊摘要

研究发现,停止GLP-1治疗可能使心脏病发作、卒中或死亡风险加倍

The BMJ · 2026-11-11

摘要

一项研究发现,对于部分2型糖尿病患者,停止GLP-1治疗与心脏病发作、卒中或死亡的联合风险增加一倍相关。既往研究表明,胰高血糖素样肽(GLP-1)受体激动剂可降低2型糖尿病患者的心脏病发作、卒中和死亡风险,但高达一半的患者在第一年内停止治疗。来自欧洲和美国的研究人员检查了80 000多名无心血管疾病史的2型糖尿病患者的数据,比较了病历和GLP-1治疗的使用情况。作者将研究结果发表于《柳叶刀区域健康-欧洲》,发现非致死性心脏病发作、非致死性卒中或全因死亡的联合风险约为两倍高(发病率

English
Stopping GLP-1 treatment could double risk of heart attack, stroke, or death, study finds

Stopping a GLP-1 treatment was linked to twice the combined risk of heart attack, stroke, or death for some people with type 2 diabetes, a study finds.Previous research indicated that glucagon-like peptide (GLP-1) receptor agonists can reduce heart attacks, strokes, and death in people with type 2 diabetes, but up to half of patients stop treatment within the first year.Researchers from Europe and the United States examined data from more than 80 000 patients with type 2 diabetes and with no history of cardiovascular disease, comparing medical records and use of GLP-1 treatments.Publishing their findings in the Lancet Regional Health Europe, the authors found that the combined risk of non-fatal heart attack, non-fatal stroke, or death from any cause was about twice as high (incidence rate

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界